Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
Notified -
Globe Newswire1-09-2025, 14:05
CORRECTION: The Global Virus Network (GVN) Escalates MPOX Emergency Response Across Africa and Beyond 2-09-2024, 11:47